Skip to content
DataLookout
Menu

NCT05879744

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

StatusTerminated
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Strategic business decision Show 4 more changesShow less
    • Final enrollment: 3 participants, 3% of the 90 planned
    • Eligibility criteria expanded, about 42 words
    • Primary completion date changed from estimate of Nov 2026 to Jun 1, 2024
    • Secondary endpoints: details revised at 3 of 7 entries
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 6 of 6 sites
    v6
  3. Minor Site details revised at 4 of 6 sitesv5
  4. Minor Site details revised at 1 of 6 sitesv4
  5. Minor Study sites: 5 to 6v3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary endpoints revised (2)
    • Start date changed from estimate of Jun 15, 2023 to May 31, 2023
    • Site details revised at 5 of 5 sites
    v2
  7. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety and tolerability of CLN-978 based on AEs, AESIs, and SAEs
Timeframe: 24 months
Define dose regimen for CLN-978
Timeframe: 24 months

Secondary (7)

Assess preliminary efficacy of CLN-978 by overall response in patients with selective histologies of R/R B-NHL
Assess preliminary efficacy of CLN-978 by complete response in patients with selective histologies of R/R B-NHL
Assess preliminary efficacy of CLN-978 by duration of response in patients with selective histologies of R/R B-NHL
Select PK parameters of CLN-978: AUC
Select PK parameters of CLN-978: Cmax
Show 2 moreShow less
Select PK parameters of CLN-978: Half-life
Immunogenicity of CLN-978 and potential impact on drug exposure

Arms and interventions

Part A Dose EscalationExperimental

Patients with R/R B-NHL treated with CLN-978 in dose escalation cohorts

Part B Dose ExpansionExperimental

Patients with R/R DLBCL, R/R FL and other R/R B-NHL treated with CLN-978 at a dose selected from the Part A Dose Escalation arm.

Drugs: CLN-978

Sites

6 sites in 1 country